What is ?

Interventional Immuno-Oncology® (IIO) is a new field that combines the physical destruction of cancer through interventional oncology procedures with synergistic drugs to provide the maximum benefit to patients.

Injecting IP-001, the leading asset in this new field, following a tumor ablation or radiation procedure is intended to transform these tumor destruction techniques into a systemically active immunotherapy.

IP-001 transforms a routine tumor ablation into a systemic immunotherapy:

A routine ablation is
performed, breaking up a targeted
tumor.

IP-001 is immediately injected into
the ablated tissue capturing liberated
tumor antigens.

The IP-001-antigen complex
interacts with antigen presenting
cells, potently activating the APCs
and increasing the uptake of tumor
neoantigens into the stimulated
immune cells.

The activated APCs process the
tumor antigens and inundate
nearby lymph nodes, triggering a
systemic T-cell response
against the cancer.
Abscopalize it!®

IP-001 transforms a routine tumor ablation into a systemic immunotherapy:

A routine ablation is
performed, breaking up a targeted
tumor.

IP-001 is immediately injected into
the ablated tissue capturing liberated
tumor antigens.

The IP-001-antigen complex
Interacts with antigen presenting
Cells, potently activating the APCs
And increasing the uptake of tumor
Neoantigens into the stimulated
immune cells.

The activated APCs process the
tumor antigens and inundate
nearby lymph nodes, triggering a
systemic T-cell response
against the cancer.
Abscopalize it!®

Immunophotonics is pioneering the field of Interventional Immuno-Oncology®, starting with its lead asset, IP-001. These routine tumor ablations and radiation procedures are occurring every single day, leaving behind valuable information around the ablation site. IP-001, which is the first Interventional Immuno-Oncology® asset to reach the clinic and has the potential to transform each of these procedures, therefore represents a multibillion-dollar de novo market opportunity.